In an increasingly tech-focused world, the use of phones, tablets, and computes, combined with social media sites, have allowed patients to find the emotional and social interactions they need when dealing with their care, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
In an increasingly tech-focused world, the use of phones, tablets, and computes, combined with social media sites, have allowed patients to find the emotional and social interactions they need when dealing with their care, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Transcript (slightly modified)
What are some of the most prominent changes you’ve seen in diabetes care as a result of an increasingly tech-focused world?
—
—
I think technology is empowering patients, whether they’re pre-diabetic patients or diabetic patients, and it’s not just accessibility. It’s not just classic telehealth. It’s the ability through ubiquitous phones and tablets and computers and censors, as well as, frankly, the comfort of individuals, whether they’re pre-diabetic or diabetic, with having emotional, social interactions online. And in some ways, we as a healthcare communityI hate to say ithave Facebook to thank for that.
That dynamic has been driven by the social media scene and it’s very relevant for seniors. They interact with their grandchildren online and so for us, pre-diabetic and diabetic seniors is a big area of focus because the fallacy, and it is a fallacy, of seniors not being able to interact with their health through technology is a very important myth for us to dispel in the healthcare world.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More